Repligen Corporation Acquires ARTeSYN Biosolutions for $200M

Repligen Acquires BioLife Solutions for $1.5 Billion

July 23, 2026

Healthcare Services

Repligen has entered into a definitive agreement to acquire BioLife Solutions in a cash-and-stock transaction with an enterprise value of approximately $1.5 billion. The deal is expected to close in the fourth quarter of 2026, subject to BioLife shareholder approval and regulatory clearances.

Artis BioSolutions To Acquire Syngoi Technologies

January 6, 2026

Biotechnology

Artis BioSolutions has signed a definitive agreement to acquire Syngoi Technologies, a Bilbao, Spain-based biotech developing enzymatic approaches for manufacturing synthetic DNA. The deal is intended to add fast, lower-cost synthetic DNA manufacturing to Artis’ gene-to-drug advanced-therapy platform, with Syngoi’s Bilbao GMP-ready facilities becoming part of Artis’ global footprint.

Artis BioSolutions Acquires Landmark Bio

April 2, 2025

Biotechnology

Artis BioSolutions, a newly launched CDMO backed by Oak HC/FT, has acquired Landmark Bio to expand capabilities for the development and manufacturing of cell and gene therapies. Landmark Bio will continue to operate as a distinct entity from its Watertown, Massachusetts headquarters while leveraging Artis' funding and platform to scale process development, GMP manufacturing, and commercialization support.

Biogen Acquires Reata Pharmaceuticals

July 28, 2023

Biotechnology

Biogen Inc. agreed to acquire Reata Pharmaceuticals, Inc. for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion. The acquisition adds Reata's FDA-approved SKYCLARYS (omaveloxolone) for Friedreich's ataxia to Biogen's rare disease portfolio and is expected to be significantly accretive to Biogen's Non-GAAP diluted EPS beginning in 2025; the transaction was anticipated to close in Q4 2023.

Sartorius Stedim Biotech Acquires Polyplus

April 13, 2023

Biotechnology

Sartorius Stedim Biotech agreed to acquire Strasbourg-based Polyplus (Polyplus‑transfection S.A.) for €2.4 billion, pending customary regulatory approvals. The transaction buys the business from private equity backers including ARCHIMED and Warburg Pincus and strengthens Sartorius’s cell & gene therapy reagent and upstream bioprocessing portfolio.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.